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Introduction {#sec005}
============

Lynch syndrome is a hereditary disorder caused by mutations in mismatch repair (MMR) genes, particularly in *MLH1* and *MSH2* and less commonly in *MSH6* and *PMS2* \[[@pone.0167354.ref001], [@pone.0167354.ref002]\]. Patients with Lynch syndrome have an increased risk of colorectal cancer (CRC) and other cancers \[[@pone.0167354.ref003], [@pone.0167354.ref004]\]. In the Chinese population, the cumulative lifetime risk of CRC in patients with *MLH1* and *MSH2* germline mutations at the age of 70 years is 81.7% and 93.1%, respectively \[[@pone.0167354.ref005]\]. However, not all people with MMR gene germline mutations develop CRC; this is partially attributable to tumor suppressor genes \[[@pone.0167354.ref006], [@pone.0167354.ref007]\].

*TP53*, one of the most crucial tumor suppressor genes, has a critical role of modulating genes that regulate defense against cancer development through inhibiting the cell cycle, angiogenesis, and cellular senescence and causing apoptosis \[[@pone.0167354.ref008]\]. *TP53* is located at the point of convergence of several distinct stress response pathways. When DNA in a cell is damaged, p53 plays a critical role in determining whether the damaged DNA will undergo the repair or apoptosis mechanism \[[@pone.0167354.ref009], [@pone.0167354.ref010]\]. This process prevents further division of cells with mutated or damaged DNA, which facilitates the prevention of tumorigenesis \[[@pone.0167354.ref007]\].

The association of *TP53* polymorphisms with CRC risk in patients with Lynch syndrome has rarely been investigated. Moreover, the results reported thus far have been inconsistent, and several studies have mainly included patients with sporadic CRC \[[@pone.0167354.ref011], [@pone.0167354.ref012], [@pone.0167354.ref013], [@pone.0167354.ref014], [@pone.0167354.ref015], [@pone.0167354.ref016]\]. Talseth et al. reported that *TP53* polymorphisms were not associated with CRC development in the Australian and Polish Lynch syndrome populations \[[@pone.0167354.ref017]\]. Furthermore, Sotamaa et al. reported that *TP53* polymorphisms may not be associated with CRC development in patients with Lynch syndrome \[[@pone.0167354.ref018]\]; this finding is consistent with that of Talseth et al. However, a cohort study conducted in the United States reported that patients with Lynch syndrome carrying the heterozygous genotype rs1042522 developed CRC 13 years earlier in life than those carrying the homozygous wild-type genotype did \[[@pone.0167354.ref019]\].

A knowledge gap exists in sporadic CRC studies because of inconsistency in the results of Lynch syndrome studies. Therefore, this study investigated whether *TP53* polymorphisms are associated with CRC risk in patients with Lynch syndrome and whether *TP53* polymorphisms interact with lifestyle factors and modify CRC risk in patients with Lynch syndrome.

Materials and Methods {#sec006}
=====================

Participant recruitment {#sec007}
-----------------------

Patients were enrolled in the Amsterdam criteria family registry of the Hereditary Nonpolyposis Colorectal Cancer Consortium of the Taiwan National Health Research Institute by using the Amsterdam II Criteria, as described in detail previously \[[@pone.0167354.ref020], [@pone.0167354.ref021]\]. From May 2002 onwards, the clinical data of all index patients with Lynch syndrome were collected. All index patients from seven participating hospitals and medical centers throughout Taiwan were screened for MMR gene germline mutations in *MLH1* and *MSH2*. In addition, the index patients were requested to contact their family members to seek permission for their enrollment in the registry.

The study was conducted in accordance with the 1975 Declaration of Helsinki, and the research protocol was approved by the Institutional Review Board of Taipei Medical University and the Taiwan National Health Research Institutes. Written informed consent was obtained from each study participant. In total, 1014 family members from 135 Amsterdam II Criteria families were registered, and their genetic analyses were completed by February 2012, as described in detail previously \[[@pone.0167354.ref021]\]. We identified 303 germline mutation carriers from the Taiwan Hereditary Nonpolyposis Colorectal Cancer Consortium. Two patients were excluded because they harbored mutations in both *MLH1* and *MSH2*. In addition, 41 patients were excluded because they did not have information on *TP53* polymorphisms. We finally recruited 260 confirmed MMR gene germline mutation carriers from 62 families.

Data collection {#sec008}
---------------

All probands and their relatives were interviewed by professional nurses in the colorectal surgery department of participating hospitals. The nurses were trained to conduct interviews and had no prior knowledge of study hypotheses regarding genetic factors, lifestyle factors, dietary intake factors, and CRC. All interviews were uniformly administered in wards by using a structured questionnaire covering questions on sociodemographic variables, lifestyle factors (cigarette smoking and alcohol, tea, and coffee consumption), and medical history.

The status of cigarette smoking and alcohol, tea, and coffee consumption was categorized as never, former, or current as described in our previous study \[[@pone.0167354.ref021]\]. We observed that few MMR gene germline mutation carriers were former cigarette smokers or alcohol, tea, or coffee consumers. Therefore, we combined the former and current users to form the "ever user" category. We biennially followed up all the participants from May 2002 to February 2012 to obtain updates about their morbidity status. The cancer diagnosis and age at diagnosis were confirmed, wherever possible, on the basis of pathology reports, medical records, cancer registry reports, and death certificates.

*TP53* polymorphisms {#sec009}
--------------------

DNA was extracted from white blood cells by using the standard procedures of phenol and chloroform extraction. *TP53* rs1042522 and rs12947788 were genotyped using the Sequenom iPLEX MassArray (Sequenom, Inc., San Diego, CA). We performed iPLEX genotyping through MALDI-TOF spectroscopy by using the Sequenom MassARRAY platform and iPLEX GOLD chemistry. We used 10 ng of genomic DNA as a template and added a PCR mix containing Qiagen HotStarTaq to the template. Shrimp alkaline phosphatase and primer extension steps were performed using the Sequenom protocol and reagents. Primers were obtained from Integrated DNA Technologies (OH, USA). Assays were designed using the MassARRAY Assay Design, Version 3.1 (Sequenom). Raw genotype data were visualized and processed using the MassARRAY Typer software, Version 4.0. Genotyping was repeated on 10% of the samples for quality control.

Statistical analysis {#sec010}
--------------------

Descriptive statistics was used to describe the sociodemographic characteristics and lifestyle factors of the MMR gene germline mutation carriers. The risk was considered to begin at birth and end at the diagnosis of CRC, death, or loss to follow-up, whichever occurred first. The MMR gene germline mutation carriers who did not receive a diagnosis of CRC were censored at the date of their last known contact or in February 2012.

The genotype distribution of each *TP53* polymorphism was examined using the Hardy--Weinberg equilibrium, and differences between expected and observed frequencies were tested for statistical significance by using Pearson's chi-square test. The identification of the MMR gene germline mutation carriers was not randomly ascertained. Thus, we adjusted for this nonrandom ascertainment by using a weighted cohort analysis approach, as described by Antoniou et al. \[[@pone.0167354.ref022]\]. A weighted Cox proportional hazard model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) to determine the association of *TP53* polymorphisms with CRC development. Mutation in MMR genes (*MLH1* or *MSH2*), sex, colonoscopy screening, and year of birth (\<1940, 1940--1949, 1950--1959, 1960--1969, 1970--1979, and \>1980) were adjusted as potential confounding factors in the multivariable Cox model. A robust sandwich covariance estimation model was used to adjust for within-cluster and within-family correlations \[[@pone.0167354.ref023]\].

Multiplicative interactions between *TP53* polymorphisms and lifestyle factors such as cigarette smoking and alcohol, tea, and coffee consumption were assessed using HRs for interactions by including their product terms in the Cox proportional model. We used the PHASE software \[[@pone.0167354.ref024]\] to reconstruct haplotypes from the genotypes of rs1042522 and rs12947788 polymorphisms for each MMR gene germline mutation carrier. The PHASE software is a Bayesian statistical method used to reconstruct haplotypes from population genotype data. The survival curves for each *TP53* polymorphism were plotted using the Kaplan--Meier method. A P value of \<0.05 was considered statistically significant, and all analyses were performed using the Statistical Analysis Software (SAS) package (Version 9.4 for Windows; SAS Institute, Inc., Cary, NC, USA). All statistical tests were two sided.

Results {#sec011}
=======

Germline mutations in *MLH1* and *MSH2* were identified from the Amsterdam II criteria families, and the diagnosis of pathologically confirmed CRC was the outcome of interest. The study population comprised 184 *MLH1* and 76 *MSH2* germline mutation carriers from 62 families, accounting for a total person time of 10,803 years. During the follow-up period, 120 (46.2%) carriers developed histologically confirmed CRC. Of these carriers, 74 (61.7%) were family members of the probands, 65 (54.2%) were women, and 96 (80.0%) were *MLH1* germline mutation carriers ([Table 1](#pone.0167354.t001){ref-type="table"}). The median age at CRC diagnosis was 44 years. Of the carriers, 186 (71.5%) never smoked cigarettes and 181 (69.6%), 102 (39.2%), and 175 (67.6%) never consumed alcohol, tea, and coffee, respectively. Furthermore, approximately 36% of the patients with CRC were born between 1950 and 1959. Approximately 135 (96.4%) of the family members were CRC free at the last date of follow-up, and colonoscopy was performed to confirm the CRC-free status.

10.1371/journal.pone.0167354.t001

###### Characteristics of MMR gene germline mutation carriers.

![](pone.0167354.t001){#pone.0167354.t001g}

  -----------------------------------------------------------------------------------------------------------------------
  Variables                                                              Total cohort (n = 260)\   CRC cases (n = 120)\
                                                                         n (%)                     n (%)
  ---------------------------------------------------------------------- ------------------------- ----------------------
  Age at diagnosis, median (IQR)[^a^](#t001fn002){ref-type="table-fn"}   44 (37--52)               

  Sex                                                                                              

  Female                                                                 139 (53.5)                65 (54.2)

  Male                                                                   121 (46.5)                55 (45.8)

  Role in study                                                                                    

  Proband                                                                51 (19.6)                 46 (38.3)

  Family member                                                          209 (80.4)                74 (61.7)

  MMR gene mutated                                                                                 

  *MLH1*                                                                 184 (70.7)                96 (80.0)

  *MSH2*                                                                 76 (29.3)                 24 (20.0)

  Cigarette smoking                                                                                

  Never                                                                  186 (71.5)                86 (71.7)

  Ever                                                                   74 (28.5)                 34 (28.3)

  Alcohol drinking                                                                                 

  Never                                                                  181 (69.6)                91 (75.8)

  Ever                                                                   79 (30.4)                 29 (24.2)

  Tea consumption                                                                                  

  Never                                                                  102 (39.2)                62 (51.7)

  Ever                                                                   158 (60.8)                58 (48.3)

  Coffee consumption                                                                               

  Never                                                                  175 (67.3)                95 (79.2)

  Ever                                                                   85 (32.7)                 25 (20.8)

  Birth cohort                                                                                     

  \<1940                                                                 25 (9.60)                 22 (18.3)

  1940--1949                                                             26 (10.0)                 17 (14.2)

  1950--1959                                                             65 (25.0)                 43 (35.8)

  1960--1969                                                             50 (19.3)                 26 (21.7)

  1970--1979                                                             56 (21.5)                 12 (10.0)

  \>1980                                                                 38 (14.6)                 \-
  -----------------------------------------------------------------------------------------------------------------------

IQR: interquartile range

^a^IQR (25^th^--75^th^ percentiles)

As presented in [Fig 1](#pone.0167354.g001){ref-type="fig"}, the results of the Kaplan--Meier CRC-free survival analysis and log-rank test revealed that the GG genotype of the rs1042522 polymorphism was significantly associated with an earlier onset of CRC compared with other genotypes (P = 0.0016). ([Fig 1](#pone.0167354.g001){ref-type="fig"}. Kaplan--Meier CRC-free survival according to the *TP53* rs1042522 single-nucleotide polymorphism \[SNP\]. The figure demonstrates an early onset of CRC in MMR gene germline mutation carriers with homozygous wild type GG genotype as compared with the heterozygous GC and homozygous variant CC genotype). The median age at CRC diagnosis for the GG, GC, and CC genotypes was 39, 45, and 51 years, respectively. In addition, the results of the log-rank test revealed that compared with other genotypes, the CC genotype of the rs12947788 polymorphism was associated with a significantly earlier onset of CRC (P = 0.0098, [Fig 2](#pone.0167354.g002){ref-type="fig"}). ([Fig 2](#pone.0167354.g002){ref-type="fig"}. Kaplan--Meier CRC-free survival according to the *TP53* rs12947788 SNP. The figure demonstrates an early onset of CRC in MMR germline mutation carriers with homozygous wild type CC genotype as compared with the heterozygous CT and homozygous variant TT genotype). The median age at CRC diagnosis for the CC, CT, and TT genotypes was 42, 45, and 47 years, respectively.

![Kaplan--Meier CRC-free survival according to the *TP53* rs1042522 single-nucleotide polymorphism (SNP).\
The figure demonstrates an early onset of CRC in MMR gene germline mutation carriers with homozygous wild type GG genotype as compared with the heterozygous GC and homozygous variant CC genotype.](pone.0167354.g001){#pone.0167354.g001}

![Kaplan--Meier CRC-free survival according to the *TP53* rs12947788 SNP.\
The figure demonstrates an early onset of CRC in MMR germline mutation carriers with homozygous wild type CC genotype as compared with the heterozygous CT and homozygous variant TT genotype.](pone.0167354.g002){#pone.0167354.g002}

[Table 2](#pone.0167354.t002){ref-type="table"} shows the association of *TP53* polymorphisms with CRC development in the patients with Lynch syndrome. Both *TP53* polymorphisms rs1042522 and rs12947788 followed the Hardy--Weinberg Equilibrium (P = 0.17 and 0.60, respectively). The adjusted HR revealed that the heterozygote variant GC and homozygote variant CC were associated with a decreased CRC risk for the rs1042522 polymorphism (HR = 0.35, 95% CI = 0.14--0.86 and HR = 0.28, 95% CI = 0.13--0.57, respectively). Further analysis revealed an association of the dominant model with a decreased CRC risk (HR = 0.32, 95% CI = 0.15--0.67). For the rs12947788 polymorphism, the heterozygote variant CT and homozygote variant TT were associated with a decreased CRC risk (HR = 0.20, 95% CI = 0.08--0.46 and HR = 0.25, 95% CI = 0.09--0.65, respectively). The dominant model of the rs12947788 polymorphism was significantly associated with a decreased CRC risk (HR = 0.21, 95% CI = 0.09--0.46).

10.1371/journal.pone.0167354.t002

###### Hazard ratios of *TP53* polymorphisms associated with CRC risk among MMR germline mutation carriers.
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  Genotype                Total cohort   Person -years   CRC cases   Crude                   Adjusted                            
  ----------------------- -------------- --------------- ----------- ----------------------- ----------- ----------------------- -----------
  ***TP53* rs1042522**                                                                                                           
  GG                      82             3273            44          1.00                                1.00                    
  GC                      118            4883            52          0.53 (0.21--1.32)       0.175       **0.35 (0.14--0.86)**   **0.022**
  CC                      60             2647            24          0.46 (0.20--1.03)       0.061       **0.28 (0.13--0.57)**   **0.001**
  Dominant model                                                                                                                 
  GG                      82             3273            44          1.00                                1.00                    
  GC+CC                   178            7530            76          0.50 (0.22--1.11)       0.091       **0.32 (0.15--0.67)**   **0.002**
  Recessive model                                                                                                                
  GG+GC                   200            8155            96          1.00                                1.00                    
  CC                      60             2647            24          0.72 (0.37--1.38)       0.319       0.60 (0.33--1.08)       0.092
  ***TP53* rs12947788**                                                                                                          
  CC                      119            4874            64          1.00                                1.00                    
  CT                      111            4629            46          **0.35 (0.17--0.71)**   **0.004**   **0.20 (0.08--0.46)**   **0.001**
  TT                      30             1300            10          **0.46 (0.22--0.96)**   **0.038**   **0.25 (0.09--0.65)**   **0.004**
  Dominant model                                                                                                                 
  CC                      119            4874            64          1.00                                1.00                    
  CT+TT                   141            5929            56          **0.37 (0.19--0.72)**   **0.003**   **0.21 (0.09--0.46)**   **0.001**
  Recessive model                                                                                                                
  CC+CT                   230            9503            110         1.00                                1.00                    
  TT                      30             1300            10          0.85 (0.47--1.52)       0.589       0.82 (0.46--1.45)       0.491

^a^ Adjusted for sex, colonoscopy screening, date of birth, familial clustering, and specific mutated MMR gene

We performed haplotype analysis to evaluate the effect of the combination of these SNPs on CRC risk in the patients with Lynch syndrome. As depicted in [Table 3](#pone.0167354.t003){ref-type="table"}, compared with the most common haplotype GC, the haplotype CT was significantly associated with a decreased CRC risk (HR = 0.26, 95% CI = 0.11--0.59). However, the haplotypes GT (HR = 0.54, 95% CI = 0.12--2.34) and CC (HR = 1.05, 95% CI = 0.58--1.89) were not significantly associated with a decreased CRC risk. Furthermore, no significant multiplicative interaction was observed between *TP53* polymorphisms and lifestyle factors ([S1 Table](#pone.0167354.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0167354.t003

###### Haplotype analysis for *TP53* polymorphism and CRC risk among MMR germline mutation carriers.
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  ----------------------------------------------------------------------------------------------------------------------
  Haplotypes                 Allele frequency\   Crude                   Adjusted                            
                             n (%)                                                                           
  -------------------------- ------------------- ----------------------- ----------- ----------------------- -----------
  **rs1042522/rs12947788**                                                                                   

  G/C                        278 (53.5)          1.00                                1.00                    

  G/T                        4 (0.8)             0.47 (0.10--2.14)       0.331       0.54 (0.12--2.34)       0.413

  C/C                        72 (13.8)           1.17 (0.65--2.10)       0.611       1.05 (0.58--1.89)       0.879

  C/T                        166 (31.9)          **0.41 (0.21--0.82)**   **0.011**   **0.26 (0.11--0.59)**   **0.001**
  ----------------------------------------------------------------------------------------------------------------------

^a^ Adjusted for sex, colonoscopy screening, date of birth, familial clustering, and specific mutated MMR gene

Discussion {#sec012}
==========

The results of the present study revealed that the GC and CC genotypes of rs1042522 and the CT and TT genotypes of rs12947788 were associated with a decreased CRC risk in the patients with Lynch syndrome in Taiwan. *TP53* rs1042522 and rs12947788 are located in exon 4 and intron 7 of chromosome 17, respectively \[[@pone.0167354.ref025]\], and have a critical role of modulating defense against cancer development. Studies have investigated the association of *TP53* polymorphisms with CRC risk, and the results reported thus far have been inconsistent \[[@pone.0167354.ref017], [@pone.0167354.ref019], [@pone.0167354.ref026], [@pone.0167354.ref027], [@pone.0167354.ref028]\]. This inconsistency may be due to differences among study populations with different allele frequencies of *TP53* polymorphisms. In the Chinese population, the C and T alleles are minor alleles with allelic frequencies of 0.431 and 0.327 for rs1042522 and rs12947788, respectively \[[@pone.0167354.ref029], [@pone.0167354.ref030]\], which are different from those in Caucasians. Moreover, these two polymorphisms are in high linkage disequilibrium (D' = 0.95).

Studies have reported an association of people with a Pro allele in their *TP53* Arg72Pro (rs1042522) polymorphism with a decreased risk of sporadic CRC \[[@pone.0167354.ref031], [@pone.0167354.ref032], [@pone.0167354.ref033]\]. However, a case--control study reported no association of the *TP53* polymorphism with CRC in patients with Lynch syndrome \[[@pone.0167354.ref034]\]. The protective effect of the C allele observed in our study can be attributed to its high efficiency in maintaining genomic integrity by arresting cells having mutated or damaged DNA in the G1 phase of the cell cycle to enable the repair mechanism or induce the apoptosis pathway \[[@pone.0167354.ref035]\]. The balance between cell cycle arrest and induced apoptosis depends on the severity of DNA damage \[[@pone.0167354.ref007]\]. When DNA is severely damaged and cannot be repaired, cells may directly induce the apoptosis pathway. However, less damaged cells may undergo the repair mechanism after being arrested in the G1 phase of the cell cycle. Thus, C allele carriers might have a low CRC risk. In addition, Tan et al. suggested that the variant Pro allele of *TP53* Arg72Pro is associated with a decreased risk of CRC because of its high efficiency in cell cycle arrest \[[@pone.0167354.ref032]\].

To the best of our knowledge, this is the first study reporting an association of the rs12947788 polymorphism with CRC in patients with Lynch syndrome. In this study, we observed that compared with MMR gene germline mutation carriers with the homozygote CC genotype, those with CT and TT genotypes were associated with a decreased CRC risk. However, the biological mechanism underlying the protective effect of the minor T allele of rs12947788 against CRC in patients with Lynch syndrome has rarely been investigated and thus remains unclear. A case--control study conducted in the Czech Republic reported that the minor T allele and heterozygote and homozygote variant genotypes of rs12947788 were associated with a decreased CRC risk \[[@pone.0167354.ref036]\]; this finding is consistent with that of our study. However, the results of Polakova et al. were not significant probably because of the low frequency of the minor allele T in both case and control groups.

Our study results revealed that carriers with the homozygote GG genotype of rs1042522 developed CRC 12 years earlier in life than those with the variant CC genotype did. This finding confirmed that the G allele is less effective in preventing CRC development. However, Jones et al. reported that Lynch syndrome carriers with a heterozygous genotype of rs1042522 developed CRC 13 years earlier in life than those with the G allele did \[[@pone.0167354.ref019]\]. This discrepancy can be attributed to the allele frequency variation of rs1042522 between Caucasian and Chinese populations. Furthermore, we observed that compared with the TT genotype, the CC genotype of rs12947788 was associated with a 4-year earlier onset of CRC.

Compared with single-SNP analysis, haplotype-based analysis is more powerful and has higher statistical power \[[@pone.0167354.ref036]\]. In this study, we determined that the haplotype C/T was protective as compared to the common haplotype G/C. However, no significant association of haplotypes containing C/T with cancer risk was observed \[[@pone.0167354.ref036], [@pone.0167354.ref037], [@pone.0167354.ref038]\]. This discrepancy can be attributed to the low frequencies of the C/T haplotype observed in these studies \[[@pone.0167354.ref036], [@pone.0167354.ref037], [@pone.0167354.ref038]\]. The identification of protective haplotypes as a host genetic factor can facilitate understanding the pathogenesis of CRC. However, additional studies are required to confirm this association.

A multiplicative interaction between *TP53* polymorphisms and lifestyle factors in patients with Lynch syndrome has not yet been reported. In this study, no significant multiplicative interactions were observed between *TP53* polymorphisms and lifestyle factors. This finding is consistent with that of a previous study that reported a nonsignificant multiplicative and additive interaction between *TP53* polymorphisms and lifestyle factors in patients with lung cancer \[[@pone.0167354.ref039]\]. Some case--control studies in India have reported a significant interaction between *TP53* polymorphisms and tobacco smoking in patients with oral and stomach cancers \[[@pone.0167354.ref040], [@pone.0167354.ref041]\]. However, these studies did not indicate P values for interaction measures and they did not include patients with Lynch syndrome; thus, drawing a conclusion from these studies is difficult.

The major strengths of our study are that all study participants were confirmed to have hereditary MMR gene germline mutations, and all CRC diagnoses were confirmed histologically. However, this study was limited by our inability to test other MMR gene germline mutations associated with Lynch syndrome, including *MSH6*, *PMS2*, and *EPCAM* germline mutations. The diagnosis of CRC was confounded by the time to access medical care services. Moreover, approximately 54% of the mutation carriers were not willing to be followed up for their recent morbidity status at least once since recruitment; hence, we likely failed to record some newly developed cancer cases. In addition, we excluded 41 patients with Lynch syndrome because their *TP53* genetic polymorphism results were unavailable. Nevertheless, demographic characteristics did not differ between included and excluded patients. In addition, we could not examine other *TP53* polymorphisms such as polymorphisms in intron 2 (rs1642785) and intron 3 (rs17878362).

In conclusion, the study results revealed that the variant C allele of rs1042522 and the variant T allele of rs12947788 were associated with a decreased CRC risk in patients with MMR gene germline mutations in Taiwan. In addition, the results revealed that MMR gene germline mutation carriers harboring rs1042522 GG and rs12947788 CC genotypes have an increased risk of early-onset CRC. Therefore, we suggest that genetic screening and regular colonoscopy be started early, particularly in patients with Lynch syndrome harboring risk alleles.
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